Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503490 | 0.90 | KDM4E (0.40) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL28203429 | 0.88 | ALDH1A1 (0.43) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL23640028 | 0.87 | EPHX2 (0.46) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL18438090 | 0.82 | EPHX2 (0.42) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL5760447 | 0.81 | TSHR (0.44) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL1087862 | 0.80 | EPHX1 (0.55) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL28309712 | 0.80 | ALDH1A1 (0.40) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL2225265 | 0.79 | KDM4E (0.40) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL18440963 | 0.78 | KDM4E (0.50) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 | |
| SCHEMBL5309693 | 0.78 | KDM4E (0.47) | KDM4ECHRM2CHRM5CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822262-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11091456-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-3822262-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2021-05-19 | — | — | EP | disclosed |
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20190270718-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10351545-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-10167272-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-01-01 | — | — | US | disclosed |
| EP-3331869-A1 | MUSCARINIC AGONISTS | Heptares Therapeutics Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2008016811-A2 | AMINOPIPERIDINES AND REALTED COMPOUNDS | NEUROGEN CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091456-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
| US-20190270718-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
| US-10351545-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
| US-20180155315-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
| US-10167272-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | KDM4E 2872/4885CHRM2 2/4885CHRM5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.